Chronic Myelomonocytic Leukemia Market Size
Market Size in USD Mn
CAGR6.6%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 6.6% |
| Market Concentration | Medium |
| Major Players | Immune-Onc Therapeutics, Stemline Therapeutics, Otsuka Pharmaceutical, Novartis, Merck Sharp & Dohme and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Chronic Myelomonocytic Leukemia Market Analysis
The chronic myelomonocytic leukemia market is estimated to be valued at USD 1012.9 Mn in 2025 and is expected to reach USD 1584.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032. According to recent studies, prevalence of chronic myelomonocytic leukemia has increased by 1.5% annually over the past 5 years. Furthermore, ongoing R&D and clinical trials for novel combination therapies and targeted drugs for treatment of CML indicate promising growth opportunities for players in this market.